| This week's sponsor is SynteractHCR. | | | |
Featured Story | | | Thursday, August 31, 2017 Corporate venture capital has long been an important source of capital for early-stage biotechs and shows no signs of diminishing, with more and more biopharma companies stepping up their investment activity. |
|
|
Top Stories Thursday, August 31, 2017 Daiichi Sankyo has cut and run from its $650 million pain alliance with Charleston Laboratories. The decision comes seven months after the FDA knocked back a request for approval of the collaboration’s top prospect. Thursday, August 31, 2017 Incyte has presented data suggesting its IDO1 enzyme inhibitor dials up the effect Keytruda has on advanced melanoma patients. The interim phase 1/2 readout paints the Incyte-Merck combination as a potential improvement over Bristol-Myers Squibb’s incumbent CTLA-4-PD-1 cocktail. Thursday, August 31, 2017 German pharma Bayer has sent its BLA to the FDA for its long-acting Hemophilia A medication BAY94-9027. Wednesday, August 30, 2017 Personalized cancer treatments known as CAR-T cells have dominated the headlines lately, but they are labor-intensive and expensive to make, and they can attack healthy tissues in the body. Fred Hutch scientists have created nanoparticles that could address both those shortcomings. Thursday, August 31, 2017 CRISPR is typically used to edit disease-causing gene mutations, but is increasingly being tapped for broader applications. The latest? Identifying sequences that activate genes, which could help unravel the causes of autoimmune disease. Thursday, August 31, 2017 Downtrodden Teva Wednesday got some good news—and Neurocrine got some company. The FDA approved the Israeli drugmaker’s Austedo to treat movement disorder tardive dyskinesia (TD) in adults, marking the med’s second approval. It won its first go-ahead in early April as a therapy for another movement disorder, chorea, which is associated with Huntington’s disease. Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. 2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Now Accepting Applications: Fierce Innovation Awards Life Science Edition FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 